Literature DB >> 19514039

Combinatorial strategies by marine cyanobacteria: symplostatin 4, an antimitotic natural dolastatin 10/15 hybrid that synergizes with the coproduced HDAC inhibitor largazole.

Kanchan Taori1, Yanxia Liu, Valerie J Paul, Hendrik Luesch.   

Abstract

Combinatorial biosynthesis meets combinatorial pharmacology, cyanobacterial style: A new antimitotic natural product with features of both dolastatins 10 and 15 was isolated from the same Floridian Symploca sp. sample that produced the histone deacetylase inhibitor largazole. Both agents in combination are more effective in inhibiting cancer cell proliferation than either agent alone.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19514039     DOI: 10.1002/cbic.200900192

Source DB:  PubMed          Journal:  Chembiochem        ISSN: 1439-4227            Impact factor:   3.164


  20 in total

Review 1.  Biologically active secondary metabolites from marine cyanobacteria.

Authors:  Joshawna K Nunnery; Emily Mevers; William H Gerwick
Journal:  Curr Opin Biotechnol       Date:  2010-10-26       Impact factor: 9.740

2.  Stereoselective Syntheses of α,β-Unsaturated γ-Amino Esters Through Phosphine-Catalyzed γ-Umpolung Additions of Sulfonamides to γ-Substituted Allenoates.

Authors:  Qing-Fa Zhou; Kui Zhang; Ohyun Kwon
Journal:  Tetrahedron Lett       Date:  2015-06-03       Impact factor: 2.415

3.  Underestimated biodiversity as a major explanation for the perceived rich secondary metabolite capacity of the cyanobacterial genus Lyngbya.

Authors:  Niclas Engene; Hyukjae Choi; Eduardo Esquenazi; Erin C Rottacker; Mark H Ellisman; Pieter C Dorrestein; William H Gerwick
Journal:  Environ Microbiol       Date:  2011-04-07       Impact factor: 5.491

Review 4.  Biological targets and mechanisms of action of natural products from marine cyanobacteria.

Authors:  Lilibeth A Salvador-Reyes; Hendrik Luesch
Journal:  Nat Prod Rep       Date:  2015-03       Impact factor: 13.423

5.  Targeted natural products discovery from marine cyanobacteria using combined phylogenetic and mass spectrometric evaluation.

Authors:  Lilibeth A Salvador-Reyes; Niclas Engene; Valerie J Paul; Hendrik Luesch
Journal:  J Nat Prod       Date:  2015-01-30       Impact factor: 4.050

6.  Design of Gallinamide A Analogs as Potent Inhibitors of the Cysteine Proteases Human Cathepsin L and Trypanosoma cruzi Cruzain.

Authors:  Paul D Boudreau; Bailey W Miller; Laura-Isobel McCall; Jehad Almaliti; Raphael Reher; Ken Hirata; Thu Le; Jair L Siqueira-Neto; Vivian Hook; William H Gerwick
Journal:  J Med Chem       Date:  2019-10-04       Impact factor: 7.446

7.  Antineoplastic agents. 590. X-ray crystal structure of dolastatin 16 and syntheses of the dolamethylleuine and dolaphenvaline units.

Authors:  George R Pettit; Thomas H Smith; Jun-Ping Xu; Delbert L Herald; Erik J Flahive; Collin R Anderson; Paul E Belcher; John C Knight
Journal:  J Nat Prod       Date:  2011-05-03       Impact factor: 4.050

Review 8.  Largazole: from discovery to broad-spectrum therapy.

Authors:  Jiyong Hong; Hendrik Luesch
Journal:  Nat Prod Rep       Date:  2012-02-14       Impact factor: 13.423

9.  Caldora penicillata gen. nov., comb. nov. (cyanobacteria), a pantropical marine species with biomedical relevance.

Authors:  Niclas Engene; Ana Tronholm; Lilibeth A Salvador-Reyes; Hendrik Luesch; Valerie J Paul
Journal:  J Phycol       Date:  2015-08       Impact factor: 2.923

10.  The marine cyanobacterial metabolite gallinamide A is a potent and selective inhibitor of human cathepsin L.

Authors:  Bailey Miller; Aaron J Friedman; Hyukjae Choi; James Hogan; J Andrew McCammon; Vivian Hook; William H Gerwick
Journal:  J Nat Prod       Date:  2013-12-23       Impact factor: 4.050

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.